Table 2.

Protocol-prespecified exploratory analysis of the association between median PFS, median OS, and exposure of ICIs and the incidence of all-grade trAEs and grade ≥3 trAEs after adjusting for the line of systemic treatment, treatment type, and type of ICIs

Variable	All-grade trAEs				Grade ≥3 trAEs
	number of treatment groups	or	95% Cl	p value	number of treatment groups	or	95% Cl	p value
Median PFS	25	0.97	0.70–1.36	0.862	22	0.80	0.59–1.08	0.129
Median OS	22	1.13	1.03–1.23	0.010	19	1.05	0.995–1.11	0.071
Median exposure	20	1.14	0.96–1.35	0.128	19	1.07	0.98–1.17	0.114

trAE, treatment-related adverse event; PFS, progression-free survival; OS, overall survival.